Table 2.
Epidemiological, clinical and pathological patterns of patients diagnosed with ovarian, fallopian tube and primary peritoneal cancer (n = 58).
| Pre-Pandemic (2019) | Pandemic with High Restrictions (2020) |
Pandemic Recovery (2021) | p | |
|---|---|---|---|---|
| Number of patients, n | 18 | 20 | 20 | |
| Age at diagnosis, median (IQR; Min-Max), years | 62.5 (18; 38–79) | 63.5 (17; 31–84) | 63 (27; 28–82) | 0.759 |
| Postmenopausal status, n (%) | 14 (77.8) | 17 (85.0) | 15 (75.0) | 0.724 |
|
Histological type, n (%) Serous Endometrioid Mucinous Clear cells Undifferentiated Carcinosarcoma Mixed Borderline Malignant non-epithelial tumors Unknown |
8 (44.4) 1 (5.6) 2 (11.1) 0 (0.0) 3 (16.7) 0 (0.0) 1 (5.6) 0 (0.0) 2 (11.1) 1 (5.6) |
12 (60.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 1 (5.0) 3 (15.0) 0 (0.0) 3 (15.0) |
4 (20.0) 0 (0.0) 0 (0.0) 2 (10.0) 1 (5.0) 1 (5.0) 0 (0.0) 9 (45.0) 2 (10.0) 1 (5.0) |
0.018 * |
|
Tumor staging 1, n (%) Initial stage (I-II) Advanced stage (III-IV) Unknown |
7 (38.9) 10 (55.6) 1 (5.6) |
11 (55.0) 9 (45.0) 0 (0.0) |
14 (70.0) 6 (30.1) 0 (0.0) |
0.254 |
| Time between first MDTM and treatment initiation, median (IQR; Min-Max), days | 34.0 (23; 1–49) | 22.0 (22; 1–104) | 36.0 (29; 5–215) | 0.293 |
| Neoadjuvant therapy, n (%) | 6 (33.3) | 11 (55.0) | 2 (10.0) | 0.010 * |
|
Diagnostic/staging surgery Laparoscopy, n (%) Laparotomy, n (%) |
4 (66.7) 2 (33.3) |
7 (100.0) 0 (0.0) |
6 (66.7) 3 (33.3) |
0.221 |
|
Primary cytoreductive surgery Laparoscopy, n (%) Laparotomy, n (%) Laparotomy preceded by diagnostic laparoscopy, n (%) |
0 (0.0) 4 (50.0) 4 (50.0) |
1 (11.1) 5 (55.6) 3 (33.3) |
0 (0.0) 10 (100.0) 0 (0.0) |
0.073 |
|
Interval debulking surgery Laparotomy, n (%) Laparotomy preceded by diagnostic laparoscopy, n (%) |
2 (100.0) 0 (0.0) |
3 (37.5) 5 (62.5) |
0 (0.0) 1 (100.0) |
0.179 |
| Hospitalization days 2, median (IQR; Min-Max) | 8.0 (9; 1–21) | 6.0 (5; 2–21) | 5.5 (4; 2–22) | 0.143 |
| Intra- and post-operative complications 3, n (%) | 3 (21.4) | 2 (11.8) | 3 (16.7) | 0.768 |
| Time between surgery and histological assessment, median (IQR; Min-Max), days | 15.0 (29; 1–45) | 13.5 (8; 6–31) | 11.0 (11; 3–51) | 0.693 |
| Time between surgery and adjuvant therapy, median (IQR; Min-Max), days | 49.5 (29; 21–63) | 42.0 (31; 29–71) | 79.0 (37; 64–108) | 0.016 * |
Legend: IQR—interquartile range; MDTM—multidisciplinary team meeting. 1 Tumor staging was assessed using the International Federation of Gynecology and Obstetrics (FIGO) Classification 2014 [20]. 2 Hospitalization days refer to the first surgical intervention. 3 Intra- and post-operative complications were considered for all surgical procedures; pre-pandemic (2019): infection of the surgical wound (n = 1), paralytic ileus (n = 1), thrombophlebitis (n = 1); pandemic with high restrictions (2020): infection of the surgical wound (n = 1), bowel injury and peritonitis (n = 1); pandemic recovery (2021): postoperative infection (n = 1), hemoperitoneum (n = 1), ureter injury (n = 1). * Statistically significant differences for a significance level of 0.05.